270 related articles for article (PubMed ID: 28508387)
1. No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
Rodríguez-Jiménez P; Chicharro P; Godoy A; Llamas-Velasco M; García M; Daudén E
Br J Dermatol; 2017 Sep; 177(3):862-863. PubMed ID: 28508387
[No Abstract] [Full Text] [Related]
2. Long persistence of tumour necrosis factor-α antagonist-induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis.
Hoffmann JHO; Knoop C; Enk AH; Hadaschik EN
Br J Dermatol; 2018 Jan; 178(1):e9-e10. PubMed ID: 28581119
[No Abstract] [Full Text] [Related]
3. Increase in antinuclear antibody levels through biologic treatment for psoriasis.
Miki M; Endo C; Naka Y; Fukuya Y; Kobayashi S; Kawashima M; Tsunemi Y
J Dermatol; 2019 Feb; 46(2):e50-e51. PubMed ID: 30051919
[No Abstract] [Full Text] [Related]
4. Different Responses to Ustekinumab of Two HLA-Cw6-positive Homozygous Twins with Psoriasis.
Burlando M; Cozzani E; Campisi C; Di Costanzo A; Parodi A
Acta Derm Venereol; 2016 Aug; 96(6):858-9. PubMed ID: 26714660
[No Abstract] [Full Text] [Related]
5. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
6. Interaction between Smoking and HLA-C*06:02 on the Response to Ustekinumab in Psoriasis.
Svedbom A; Nikamo P; Ståhle M
J Invest Dermatol; 2020 Aug; 140(8):1653-1656.e1. PubMed ID: 32014510
[No Abstract] [Full Text] [Related]
7. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.
Menting SP; van den Reek JM; Baerveldt EM; de Jong EM; Prens EP; Lecluse LL; Wolbink GJ; Van der Kleij D; Spuls PI; Rispens T
Br J Dermatol; 2015 Sep; 173(3):855-7. PubMed ID: 25865153
[No Abstract] [Full Text] [Related]
8. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
Assefa GT; Kaneko S; Oguro H; Morita E
J Dermatol; 2019 Mar; 46(3):e112-e113. PubMed ID: 30151838
[No Abstract] [Full Text] [Related]
9. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
[No Abstract] [Full Text] [Related]
10. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
Hoffmann JH; Hartmann M; Enk AH; Hadaschik EN
Br J Dermatol; 2011 Dec; 165(6):1355-8. PubMed ID: 21801160
[TBL] [Abstract][Full Text] [Related]
11. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre.
Vergou T; Moustou AE; Antoniou C
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e40-e41. PubMed ID: 27038363
[No Abstract] [Full Text] [Related]
12. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
[No Abstract] [Full Text] [Related]
13. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
14. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
[No Abstract] [Full Text] [Related]
15. Ustekinumab as therapy for psoriasis in a 2-year-old girl.
Min MS; Shroff A; Rose S; Lebwohl M; Guttman-Yassky E
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e109-e110. PubMed ID: 26377248
[No Abstract] [Full Text] [Related]
16. Clearance of annular pustular psoriasis with ustekinumab.
Schnabel V; Broekaert SMC; Schön MP; Mössner R
Eur J Dermatol; 2017 Jun; 27(3):296-297. PubMed ID: 28202422
[No Abstract] [Full Text] [Related]
17. A case of psoriasis and systemic lupus erythematous successfully treated with ustekinumab.
Nogueira M; Selores M; Torres T
Eur J Dermatol; 2021 Jun; 31(3):429-431. PubMed ID: 34309535
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
[No Abstract] [Full Text] [Related]
19. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
[No Abstract] [Full Text] [Related]
20. Response of superimposed linear psoriasis to ustekinumab: A case report.
Weng HJ; Tsai TF
Indian J Dermatol Venereol Leprol; 2017; 83(3):392-396. PubMed ID: 28366906
[No Abstract] [Full Text] [Related]
[Next] [New Search]